Last updated: 15:40
No Notes Added Yet
QMS Medical Allied Services Ltd is a reputable company that specializes in providing comprehensive medical and allied services. With a commitment to excellence, they offer a wide range of healthcare solutions to meet the needs of patients, medical professionals, and healthcare institutions. Their services encompass medical staffing, healthcare consulting, medical equipment supply, and facility management. QMS Medical Allied Services Ltd prides itself on its highly skilled and experienced team of medical professionals, administrators, and supp...Read More
QMS Medical Allied Services Ltd is a reputable company that specializes in providing comprehensive medical and allied services. With a commitment to excellence, they offer a wide range of healthcare solutions to meet the needs of patients, medical professionals, and healthcare institutions. Their services encompass medical staffing, healthcare consulting, medical equipment supply, and facility management. QMS Medical Allied Services Ltd prides itself on its highly skilled and experienced team of medical professionals, administrators, and support staff who work diligently to ensure the delivery of top-quality healthcare services. They maintain stringent quality control measures to uphold the highest standards of patient care, regulatory compliance, and customer satisfaction. The company places a strong emphasis on continuous improvement, staying up-to-date with the latest advancements in medical technology and best practices. QMS Medical Allied Services Ltd is recognized for its reliability, efficiency, and customer-centric approach, making it a trusted partner in the healthcare industry. Whether it's providing staffing solutions for medical facilities or delivering specialized healthcare consulting services, the company is dedicated to improving healthcare outcomes and fostering a healthier community. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹174 Cr.
Stock P/E 19.3
P/B 1.7
Current Price ₹90
Book Value ₹ 53.5
Face Value 10
52W High ₹110.5
Dividend Yield 0.56%
52W Low ₹ 69
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|---|---|
| Net Sales | 25 | 27 | 21 | 31 | 26 |
| Other Income | 0 | 0 | 0 | 0 | 0 |
| Total Income | 25 | 28 | 21 | 32 | 26 |
| Total Expenditure | 23 | 25 | 17 | 28 | 21 |
| Operating Profit | 2 | 3 | 4 | 3 | 5 |
| Interest | 1 | 1 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 2 | 3 | 2 | 3 |
| Provision for Tax | 0 | 1 | 1 | 1 | 1 |
| Profit After Tax | 1 | 2 | 3 | 2 | 2 |
| Adjustments | 0 | -0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 2 | 3 | 2 | 2 |
| Adjusted Earnings Per Share | 0.4 | 1.1 | 1.4 | 0.9 | 1.4 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Net Sales | 52 | 73 | 122 | 146 | 104 | 122 | 105 |
| Other Income | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Total Income | 52 | 73 | 122 | 148 | 105 | 123 | 107 |
| Total Expenditure | 47 | 63 | 105 | 130 | 93 | 104 | 91 |
| Operating Profit | 5 | 10 | 17 | 18 | 12 | 19 | 15 |
| Interest | 0 | 1 | 1 | 2 | 2 | 3 | 3 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 3 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 4 | 9 | 15 | 14 | 9 | 12 | 10 |
| Provision for Tax | 1 | 2 | 4 | 4 | 2 | 3 | 4 |
| Profit After Tax | 3 | 6 | 11 | 11 | 6 | 9 | 9 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 3 | 6 | 11 | 11 | 6 | 9 | 9 |
| Adjusted Earnings Per Share | 2 | 4.2 | 7.3 | 7.1 | 3.6 | 5 | 4.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 17% | 0% | 19% | 0% |
| Operating Profit CAGR | 58% | 4% | 31% | 0% |
| PAT CAGR | 50% | -6% | 25% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 4% | -15% | NA% | NA% |
| ROE Average | 12% | 22% | 48% | 57% |
| ROCE Average | 15% | 20% | 36% | 40% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|
| Shareholder's Funds | 3 | 9 | 20 | 31 | 70 | 79 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 1 | 2 | 1 | 2 |
| Other Non-Current Liabilities | -0 | -0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 15 | 24 | 39 | 52 | 46 | 56 |
| Total Liabilities | 18 | 33 | 60 | 85 | 118 | 137 |
| Fixed Assets | 0 | 3 | 10 | 8 | 25 | 24 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 5 | 6 |
| Total Current Assets | 18 | 30 | 50 | 77 | 88 | 107 |
| Total Assets | 18 | 33 | 60 | 85 | 118 | 137 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 1 | 1 | 2 | 1 |
| Cash Flow from Operating Activities | -4 | -3 | 2 | -2 | -8 | 1 |
| Cash Flow from Investing Activities | -0 | -4 | -8 | 2 | -25 | -3 |
| Cash Flow from Financing Activities | 5 | 7 | 7 | 0 | 32 | 0 |
| Net Cash Inflow / Outflow | 0 | 1 | 1 | 1 | -1 | -1 |
| Closing Cash & Cash Equivalent | 0 | 1 | 1 | 2 | 1 | 0 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 2.02 | 4.22 | 7.25 | 7.1 | 3.57 | 5.04 |
| CEPS(Rs) | 2.04 | 4.46 | 7.74 | 7.87 | 4.17 | 6.97 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0.5 | 0.5 |
| Book NAV/Share(Rs) | 2.03 | 6.25 | 13.5 | 20.62 | 39.44 | 43.99 |
| Core EBITDA Margin(%) | 8.96 | 13.2 | 13.93 | 11.37 | 10.89 | 15.02 |
| EBIT Margin(%) | 8.92 | 12.76 | 13.37 | 11.55 | 10.57 | 12.58 |
| Pre Tax Margin(%) | 8.43 | 11.99 | 12.21 | 9.88 | 8.37 | 10.02 |
| PAT Margin (%) | 5.85 | 8.74 | 8.95 | 7.3 | 6.13 | 7.37 |
| Cash Profit Margin (%) | 5.92 | 9.23 | 9.55 | 8.1 | 7.16 | 10.19 |
| ROA(%) | 16.97 | 24.76 | 23.27 | 14.7 | 6.27 | 7.05 |
| ROE(%) | 99.46 | 102.03 | 73.44 | 41.62 | 12.58 | 12.09 |
| ROCE(%) | 60.89 | 64.85 | 53.55 | 32.83 | 13.83 | 14.7 |
| Receivable days | 56.39 | 48.25 | 51.14 | 81.1 | 142.24 | 120.2 |
| Inventory Days | 62.98 | 61.84 | 53.84 | 55.58 | 95.04 | 100.89 |
| Payable days | 79.4 | 69.29 | 59.68 | 58.07 | 84.96 | 89.36 |
| PER(x) | 0 | 0 | 0 | 0 | 36.16 | 22.94 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 3.28 | 2.63 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0.38 | 0.43 |
| EV/Net Sales(x) | 0.09 | 0.19 | 0.18 | 0.23 | 2.46 | 1.99 |
| EV/Core EBITDA(x) | 0.95 | 1.45 | 1.29 | 1.86 | 21.26 | 12.93 |
| Net Sales Growth(%) | 0 | 40.17 | 67.77 | 19.9 | -28.9 | 17.38 |
| EBIT Growth(%) | 0 | 100.39 | 75.82 | 3.55 | -34.93 | 39.74 |
| PAT Growth(%) | 0 | 109.43 | 71.72 | -2.11 | -40.32 | 41.14 |
| EPS Growth(%) | 0 | 109.43 | 71.72 | -2.11 | -49.68 | 41.14 |
| Debt/Equity(x) | 1.49 | 1.23 | 0.96 | 1.03 | 0.36 | 0.44 |
| Current Ratio(x) | 1.2 | 1.25 | 1.28 | 1.48 | 1.9 | 1.93 |
| Quick Ratio(x) | 0.63 | 0.6 | 0.76 | 1.01 | 1.25 | 1.26 |
| Interest Cover(x) | 18.06 | 16.6 | 11.58 | 6.93 | 4.81 | 4.91 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0.11 | 0.17 |
| # | Dec 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 73.67 | 73.67 | 73.67 | 73.67 | 73.67 | 73.67 | 73.67 | 68.11 | 68.11 |
| FII | 0.71 | 1.21 | 1.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.6 | 1.59 |
| Public | 25.63 | 25.12 | 25.31 | 26.33 | 26.33 | 26.33 | 26.33 | 30.28 | 30.3 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.31 | 1.31 | 1.31 | 1.31 | 1.31 | 1.31 | 1.31 | 1.32 | 1.32 |
| FII | 0.01 | 0.02 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.03 | 0.03 |
| Public | 0.46 | 0.45 | 0.45 | 0.47 | 0.47 | 0.47 | 0.47 | 0.59 | 0.59 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.93 | 1.93 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
